12:00 AM
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CTP-6: Phase III data

Pooled data from 475 patients with confirmed HER2-positive metastatic breast cancer in the intent-to-treat (ITT) populations of 2 double-blind, international Phase I/IIb and III trials showed that CTP-6 plus paclitaxel was equivalent to Herceptin trastuzumab plus paclitaxel based on the primary endpoint of ORR (57% vs. 62%, 95% CI: -0.14, 0.04). Hospira said the limits of the 95% CI for the difference...

Read the full 297 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >